What is the 13F Pro Quality Score for MAIA?

13F Pro ranks MAIA Biotechnology, Inc. (MAIA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MAIA's current score at https://13fpro.ai/research/MAIA (free sign-up required for the full ranking).

Where does 13F Pro source MAIA data?

All MAIA Biotechnology, Inc. fundamentals and ownership data come directly from SEC EDGAR. MAIA Biotechnology, Inc. files with the SEC under CIK 1878313. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MAIA in?

MAIA Biotechnology, Inc. (MAIA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MAIA research updated on 13F Pro?

MAIA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MAIA Biotechnology, Inc.(MAIA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1878313 MAIA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MAIA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MAIA Biotechnology, Inc. (MAIA), a Healthcare sector company. MAIA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), MAIA Biotechnology, Inc. reports net income of $-6.4M, free cash flow of $-5.3M. Top institutional holders of MAIA by reported 13-F value include Solas Capital Management,, Alyeska Investment Group, L.P., VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MAIA trades on the NYSE exchange and files with the SEC under CIK 1878313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MAIA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MAIA Biotechnology, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-6.4M

Free Cash Flow

Q1 2026

$-5.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $0.00FY23 $0.00FY24 $0.00FY25 —

Net Income

+3.7% YoY

$-22.4MFY 2025

FY22 —FY23 —FY24 $-23.3MFY25 $-22.4M

Operating Income

-43.1% YoY

$-24.3MFY 2025

FY22 $-16.2MFY23 $-20.2MFY24 $-17.0MFY25 $-24.3M

EPS (Diluted)

+33.3% YoY

$-0.70FY 2025

FY22 $-1.75FY23 $-1.49FY24 $-1.05FY25 $-0.70

Total Assets

-4.4% YoY

$9.7MFY 2025

FY22 $12.0MFY23 $7.6MFY24 $10.2MFY25 $9.7M

Op. Cash Flow

-20.0% YoY

$-18.8MFY 2025

FY22 $-12.1MFY23 $-13.1MFY24 $-15.7MFY25 $-18.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	—	$0.00	$0.00	$0.00
Net Income	$-22.4M +3.7%	$-23.3M	—	—
Operating Income	$-24.3M -43.1%	$-17.0M +16.0%	$-20.2M -24.8%	$-16.2M
EPS (Diluted)	$-0.70 +33.3%	$-1.05 +29.5%	$-1.49 +14.9%	$-1.75
Total Assets	$9.7M -4.4%	$10.2M +34.2%	$7.6M -37.1%	$12.0M
Operating Cash Flow	$-18.8M -20.0%	$-15.7M -20.1%	$-13.1M -8.1%	$-12.1M

AI Insight: MAIA Financial Trends

MAIA is a pre-revenue biotech with persistent operating losses and volatile equity, most recently $28M in Q1 2026.

• Operating losses stable at $4–5M per quarter Q2 2024–Q1 2025, then widened to $7–9M in Q3 2025–Q1 2026.

• Operating cash outflow deteriorated to $7M in Q4 2025, worst quarter on record; improved slightly to $5M in Q1 2026.

• Equity swung from $4M (Q2 2025) to $0M (Q3 2025) to $28M (Q1 2026), signaling recent capital raise.

⚠ No revenue generation visible across all eight quarters; company burning cash with no disclosed commercialization milestone.

⚠ Q1 2026 equity spike to $28M likely from fundraising—monitor burn rate relative to new cash to assess runway.

AI Insight: MAIA Ratio Trends

MAIA shows deep losses with negative ROE of -91.8% in Q1 2026, indicating substantial cash burn and no path to profitability yet visible.

• ROA deteriorated to -72.1% in Q1 2026, reflecting ongoing operating losses and inefficient asset deployment.

• TTM ROIC stands at -92.9%, demonstrating the company is destroying shareholder capital at scale.

⚠ Nearly all financial ratios unavailable prior to Q1 2026; limited historical context to assess trajectory or improvement.

⚠ Sustained negative returns on equity and assets suggest clinical or commercial inflection needed to restore investor value.

Get alerted when MAIA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MAIA Biotechnology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MAIA

Solas Capital Management, LLC
$6.0M4,297,004 sh
Alyeska Investment Group, L.P.
$3.5M2,500,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.9M2,074,045 sh
683 Capital Management, LLC
$1.5M1,066,666 sh
Centric Wealth Management
$1.1M796,723 sh
Cable Car Capital, LP
$907.9K648,503 sh
Bleichroeder LP
$700.0K500,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$504.9K360,481 sh
VANGUARD FIDUCIARY TRUST CO
$279.0K199,314 sh
STATE STREET CORP
$194.5K138,950 sh

Fund	Value	Shares
Solas Capital Management, LLC	$6.0M	4,297,004
Alyeska Investment Group, L.P.	$3.5M	2,500,000
VANGUARD CAPITAL MANAGEMENT LLC	$2.9M	2,074,045
683 Capital Management, LLC	$1.5M	1,066,666
Centric Wealth Management	$1.1M	796,723
Cable Car Capital, LP	$907.9K	648,503
Bleichroeder LP	$700.0K	500,000
GEODE CAPITAL MANAGEMENT, LLC	$504.9K	360,481
VANGUARD FIDUCIARY TRUST CO	$279.0K	199,314
STATE STREET CORP	$194.5K	138,950

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MAIA on your watchlist

Track score changes the day MAIA Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MAIA a good stock to buy?

13F Pro's AI-powered analysis of MAIA Biotechnology, Inc. (MAIA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MAIA are available on the MAIA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MAIA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MAIA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MAIA Biotechnology, Inc.'s investment landscape.